Porphyromonas gingivalis, a bacterium tied to gum disease, was found at markedly higher levels in calcified aortic valves from patients with severe CAVS than in valves from other heart-disease patients.
Mouse experiments suggested a causal role: repeated exposure led the bacteria to accumulate in aortic valves, increasing calcification and other CAVS features, while preventive antibiotics significantly reduced those effects.
Human valve-cell studies traced the mechanism to IL-1β-driven inflammation, and knocking out IL-1β in mice cut calcification and symptoms even when P. gingivalis was present.
CAVS is the world’s most common valvular heart disease and currently has no proven drug therapy—patients generally need valve replacement surgery—so the findings point to oral health and inflammation as possible prevention or treatment avenues.
Could a trip to the dentist one day prevent the need for open-heart surgery?
How can new antibody drugs penetrate hardened heart valves to stop the inflammation caused by oral bacteria?
Unveiling the Oral-Heart Connection: How Gum Disease Bacteria Drive Aortic Valve Calcification and the Future of Integrated Prevention
Overview
Recent scientific breakthroughs have revealed a strong link between gum disease bacteria, especially Porphyromonas gingivalis, and the calcification of the aortic valve. Studies show that P. gingivalis is present in calcified aortic valve tissues and can trigger an inflammatory response through the IL-1β pathway. This inflammation is believed to contribute directly to the calcification process. Evidence from both human tissue analysis and animal experiments supports this connection, highlighting the importance of oral health in preventing serious heart conditions and opening new possibilities for targeted therapies.